{"id":"NCT02387801","sponsor":"Eli Lilly and Company","briefTitle":"A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis","officialTitle":"Early Onset of Clinical Improvement With Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2015-09","completion":"2016-08","firstPosted":"2015-03-13","resultsPosted":"2016-10-21","lastUpdate":"2019-09-18"},"enrollment":12,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]}],"arms":[{"label":"Ixekizumab Dosing Q2W","type":"EXPERIMENTAL"},{"label":"Ixekizumab Dosing Q4W","type":"EXPERIMENTAL"}],"summary":"To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.","primaryOutcome":{"measure":"Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score","timeFrame":"Baseline through Week 12","effectByArm":[{"arm":"Ixekizumab Q2W","deltaMin":5,"sd":null},{"arm":"Ixekizumab Q4W","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29785237"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Upper respiratory tract infection","Injection site erythema","Injection site urticaria","Influenza","Biopsy breast"]}}